» Articles » PMID: 31308061

Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2019 Jul 17
PMID 31308061
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Myelodysplastic syndromes (MDS) with deletion of chromosome 7q/7 [-7/(del)7q MDS] is associated with worse outcomes and needs novel insights into pathogenesis. Reduced expression of signaling protein dedicator of cytokinesis 4 (DOCK4) in patients with -7/(del)7q MDS leads to a block in hematopoietic stem cell (HSC) differentiation. Identification of targetable signaling networks downstream of DOCK4 will provide means to restore hematopoietic differentiation in MDS. We utilized phosphoproteomics approaches to identify signaling proteins perturbed as a result of reduced expression of DOCK4 in human HSCs and tested their functional significance in primary model systems.

Results: We demonstrate that reduced levels of DOCK4 lead to increased global tyrosine phosphorylation of proteins in primary human HSCs. LYN kinase and phosphatases INPP5D (SHIP1) and PTPN6 (SHP1) displayed greatest levels of tyrosine phosphorylation when DOCK4 expression levels were reduced using DOCK4-specific siRNA. Our data also found that increased phosphorylation of SHIP1 and SHP1 phosphatases were due to LYN kinase targeting these phosphatases as substrates. Increased migration and impediment of HSC differentiation were consequences of these signaling alterations. Pharmacologic inhibition of SHP1 reversed these functional aberrations in HSCs expressing low DOCK4 levels. In addition, differentiation block seen in DOCK4 haplo-insufficient [-7/(del)7q] MDS was rescued by inhibition of SHP1 phosphatase.

Conclusions: LYN kinase and phosphatases SHP1 and SHIP1 are perturbed when DOCK4 expression levels are low. Inhibition of SHP1 promotes erythroid differentiation in healthy HSCs and in -7/(del)7q MDS samples with low DOCK4 expression. Inhibitors of LYN, SHP1 and SHIP1 also abrogated increased migratory properties in HSCs expressing reduced levels of DOCK4.

Citing Articles

Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets.

Mori M, Kubota Y, Durmaz A, Gurnari C, Goodings C, Adema V Leukemia. 2023; 37(10):2082-2093.

PMID: 37634012 PMC: 10539177. DOI: 10.1038/s41375-023-02003-x.


USP36-Mediated Deubiquitination of DOCK4 Contributes to the Diabetic Renal Tubular Epithelial Cell Injury Wnt/β-Catenin Signaling Pathway.

Zhu S, Hou S, Lu Y, Sheng W, Cui Z, Dong T Front Cell Dev Biol. 2021; 9:638477.

PMID: 33968925 PMC: 8102983. DOI: 10.3389/fcell.2021.638477.


Epigenetic modifiers in normal and aberrent erythropoeisis.

Sundaravel S, Steidl U, Wickrema A Semin Hematol. 2021; 58(1):15-26.

PMID: 33509439 PMC: 7883935. DOI: 10.1053/j.seminhematol.2020.12.005.


Long Noncoding RNA Promotes the Progression of Liver Cancer via Alteration of microRNA-144-3p/DOCK4 Signal.

Li H, Wang M, Zhou H, Lu S, Zhang B Cancer Manag Res. 2020; 12:9339-9349.

PMID: 33061623 PMC: 7532886. DOI: 10.2147/CMAR.S261976.


Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy.

Zhang B, Zhong X, Sauane M, Zhao Y, Zheng Z Cells. 2020; 9(3).

PMID: 32143485 PMC: 7140432. DOI: 10.3390/cells9030621.


References
1.
Heaney M, Golde D . Myelodysplasia. N Engl J Med. 1999; 340(21):1649-60. DOI: 10.1056/NEJM199905273402107. View

2.
Wickrema A, Chen F, Namin F, Yi T, Ahmad S, Uddin S . Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol. 1999; 27(7):1124-32. DOI: 10.1016/s0301-472x(99)00043-0. View

3.
Wickrema A, Uddin S, Sharma A, Chen F, AlSayed Y, Ahmad S . Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem. 1999; 274(35):24469-74. DOI: 10.1074/jbc.274.35.24469. View

4.
Bittorf T, Seiler J, Zhang Z, Jaster R, Brock J . SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem. 1999; 380(10):1201-9. DOI: 10.1515/BC.1999.152. View

5.
Radosevic N, Taylor M, Shivakrupa , DeBerry C, Metcalfe D, Zhou M . Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. Blood. 2001; 98(2):343-50. DOI: 10.1182/blood.v98.2.343. View